Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Capital Expenditures (2022 - 2025)

Stoke Therapeutics has reported Capital Expenditures over the past 4 years, most recently at $578000.0 for Q4 2025.

  • For Q4 2025, Capital Expenditures rose 1056.0% year-over-year to $578000.0; the TTM value through Dec 2025 reached $670000.0, up 998.36%, while the annual FY2025 figure was $670000.0, 998.36% up from the prior year.
  • Capital Expenditures for Q4 2025 was $578000.0 at Stoke Therapeutics, up from $41000.0 in the prior quarter.
  • Over five years, Capital Expenditures peaked at $2.8 million in Q3 2022 and troughed at -$47000.0 in Q3 2024.
  • A 4-year average of $394312.5 and a median of $197000.0 in 2023 define the central range for Capital Expenditures.
  • Biggest five-year swings in Capital Expenditures: plummeted 112.27% in 2024 and later soared 1056.0% in 2025.
  • Year by year, Capital Expenditures stood at $409000.0 in 2022, then plummeted by 44.01% to $229000.0 in 2023, then tumbled by 78.17% to $50000.0 in 2024, then soared by 1056.0% to $578000.0 in 2025.
  • Business Quant data shows Capital Expenditures for STOK at $578000.0 in Q4 2025, $41000.0 in Q3 2025, and $24000.0 in Q2 2025.